Leukemia Research
Volume 30, Issue 4 , Pages 427-436 , April 2006

Nocodazole, a microtubule depolymerising agent, induces apoptosis of chronic lymphocytic leukaemia cells associated with changes in Bcl-2 phosphorylation and expression

Received 21 June 2005 ,Accepted 8 August 2005.

References 

  1. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–1847
  2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–1854
  3. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916
  4. Fernandez JA, Keshvara LM, Peters JD, Furlong MT, Harrison ML, Geahlen RL. Phosphorylation and activation-independent association of the tyrosine kinase Syk and the tyrosine kinase substrates Cbl and Vav with tubulin in B-cells. J Biol Chem. 1999;274:1401–1406
  5. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukaemia: revelations from the B-cell receptor. Blood. 2004;103:4389–4395
  6. Faruki S, Geahlen RL, Asai DJ. Syk-dependent phosphorylation of microtubules in activated B-lymphocytes. J Cell Sci. 2000;(113):2557–2565
  7. Peters JD, Furlong MT, Asai DJ, Harrison ML, Geahlen RL. Syk, activated by cross-linking the B-cell antigen receptor, localizes to the cytosol where it interacts with and phosphorylates alpha-tubulin on tyrosine. J Biol Chem. 1996;271:4755–4762
  8. Vasile S, Coligan JE, Yoshida M, Seon BK. Isolation and chemical characterization of the human B29 and mb-1 proteins of the B-cell antigen receptor complex. Mol Immunol. 1994;31:419–427
  9. Mateo V, Brown EJ, Biron G, Rubio M, Fischer A, Deist FL, et al. Mechanism of CD47-induced caspase-independent cell death in normal and leukemic cells: link between phosphatidylserine exposure and cytoskeleton organization. Blood. 2002;100:2882–2890
  10. Mateo V, Lagneaux L, Bron D, Biron G, Armant M, Delespesse G, et al. CD47 ligation induces caspase independent cell death in chronic lymphocytic leukaemia. Nat Med. 1999;5:1277–1284
  11. Lu D, Zhaa Y, Tawatao R, Cottam HB, Sen M, Leoni LM, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukaemia. Proc Natl Acad Sci USA. 2004;101:3118–3123
  12. Cohen HJ. Human lymphocyte surface immunoglobulin capping. Normal characteristics and anomalous behavior of chronic lymphocytic leukemic lymphocytes. J Clin Invest. 1975;55(1):84–93
  13. Flanagan J, Koch G. Cross-linked surface Ig attaches to actin. Nature. 1978;273:278–281
  14. Gabbiani G, Chaponnier C, Zumbe A, Vassalli P. Actin and tubulin co-cap with surface immunoglobulins in mouse B lymphocytes. Nature. 1977;269:697–698
  15. Moon EY, Lerner A. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. Cancer Res. 2002;62(20):5711–5719
  16. Wetherley-Mein G, Thomson A, O’Connor T, Peel W, Singh A. Colchicine ultrasensitivity of lymphocytes in chronic lymphocytic leukemia. Brit J Haematol. 1983;54:111–120
  17. Thomson A, Robinson M. Cytocidal action of colchicine in vitro on lymphocytes in chronic lymphocytic leukemia. Lancet. 1967;ii:868–870
  18. Vilpo JA, Koski T, Vilpo LM. Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro. Eur J Haematol. 2000;65(6):370–378
  19. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukaemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood. 2003;101:4098–4104
  20. Thornton PD, Fernandez C, Giustolisi GM, Morilla R, Atkinson S, A’Hern RP, et al. CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J. 2004;5:145–151
  21. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–147
  22. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardisation of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17:2257–2317
  23. Pettitt AR, Moran EC, Cawley JC. Homotypic interactions protect chronic lymphocytic leukaemia cells from spontaneous death in vitro. Leuk Res. 2001;25(11):1003–1012
  24. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med. 1992;176(5):1319–1326
  25. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood. 1998;91(7):2387–2396
  26. Blagosklonny M, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer. 1999;83:151–156
  27. Byrd JC, Lucas DM, Mone AP, Kitner JB, Drabick JJ, Grever M. KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukaemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Blood. 2003;101:4547–4550
  28. Haldar S, Basu A, Croce C. Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997;57:229–233
  29. Blagosklonny M, Giannakakou P, el-Deiry W, Kingston D, Higgs P, Neckers L, et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res. 1997;57:130–135
  30. O’Connor L, Strasser A, O’Reilly LA, Hausmann G, Adams JM, Cory S, et al. Bim—a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 1998;17:384–395
  31. Puthalakath H, Huang DCS, O’Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell. 1999;3:287–296
  32. Casola S, Otipoby KL, Alimzhanov MB, Humme S, Uyttersprot N, Kutok JL, et al. B cell receptor signal strength determines B cell fate. Nat Immunol. 2004;5:317–327
  33. Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004;117:787–800
  34. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukaemia. Blood. 2003;101:1087–1093
  35. Giannakakou P, Nakano M, Nicolaou KC, O’Brate A, Yu J, Blagosklonny MV, et al. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA. 2002;99(16):10855–10860
  36. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8 and -10 in a caspase-9 dependent manner. J Cell Biol. 1999;144:281–292
  37. Ferrari D, Stepczynska A, Los M, Wesselborg S, Schulze-Osthoff K. Differential regulation and ATP requirement for caspase-8 and caspase-3 activationduring CD95-and anti-cancer drug-induced apoptosis. J Exp Med. 1998;188:979–984
  38. Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA. 1999;96:3775–3780
  39. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N terminal protein kinase pathway normally activated at G2/M. Mol Cell Biol. 1999;19:8469–8478
  40. Fang G, Chang BS, Kim CN, Perkins C, Thompson CB, Bhalla KN. Loop” domain is necessary for Taxol induced mobility shift and phosphorylation of BCL-2 as well as for inhibiting Taxol induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res. 1998;58:3202–3208
  41. Du L, Lyle CS, Chambers TC. Characterisation of vinblastine induced BCL-XL and BCL-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction. Oncogene. 2005;24:107–117
  42. Thomas A, Pepper C, Hoy T, Bentley P. Bryostatin induces protein kinase C modulation, Mcl-1 up regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug induced apoptosis in B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma. 2004;45:997–1008
  43. Torcia M, De Chiara G, Nencioni L, Ammendola S, Labardi D, Lucibello M, et al. Nerve growth factor inhibits apoptosis in memory B lymphocytes via inactivation of p38 MAPK, prevention of Bcl-2 phosphorylation, and cytochrome c release. J Biol Chem. 2001;276:39027–39036
  44. Furukawa Y, Iwase S, Kikuchi J, Terui Y, Nakamura M, Yamada H, et al. Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation. J Biol Chem. 2000;275:21661–21667
  45. Puthalakath H, Villunger A, O’Reilly LA, Beaumont JG, Coultas L, Cheney RE, et al. BMF: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science. 2001;293:1829–1832
  46. Morales AA, Olsson A, Celsing F, Österborg A, Jondal M, Osorio LM. Expression and transcriptional regulation of functionally distinct BMF isoforms in B-chronic lymphocytic leukaemia cells. Leukemia. 2004;18:41–47
  47. Reichle A, Diddens H, Altmayr F, Rastetter J, Andreesen R. Beta-tubulin and P-glycoprotein: major determinants of vincristine accumulation in B-CLL cells. Leuk Res. 1995;19:823–829

PII: S0145-2126(05)00317-6

doi: 10.1016/j.leukres.2005.08.009

Leukemia Research
Volume 30, Issue 4 , Pages 427-436 , April 2006

Article Tools

* Image Usage & Resolution